December 8, 2025BloodOpen Access

CD34 selected stem cell boost provides robust outcomes in patients with poor graft function

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Analysis reveals CD34 stem cell boost improves hematological response in graft function issues, suggesting new treatment potential.

Overall hematological response rate to CD34 boost was 68%, indicating effectiveness in poor graft function.
Median time to CD34 boost was 127 days for one institution, highlighting variability in treatment delay.
Assessment of two cohorts revealed significant outcomes for early intervention, with p=0.016 for timing.
Use of CD34 selected stem cells shows promising results, suggesting potential for improved patient survival rates.],

Choe et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark